Machine-learning-selected plasma markers distinguish Lewy body and frontotemporal dementias
A six-cohort plasma proteomics study used cross-validated LASSO to select a 21-protein multiplex panel for dementia differential diagnosis. In the new DLB/FTD results, ITGAV and ITGAM were reduced in dementia with Lewy bodies and also tracked Lewy-body pathology in independent autopsy-confirmed cohorts; a panel including ITGAV, ITGAM and ERBB3 distinguished DLB from controls and Alzheimer dementia in an independent multicenter cohort. For frontotemporal dementia, NfL and B4GAT1 contributed to the panel distinguishing FTD from controls. Validation-set AUCs were 0.83 for DLB versus controls, 0.78 for DLB versus Alzheimer dementia, 0.85 for FTD versus controls and 0.77 for FTD versus Alzheimer dementia.
Technology: Cross-validated LASSO regression and multivariable logistic-regression models applied to Olink proximity-extension plasma proteomics
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A six-cohort plasma proteomics study used cross-validated LASSO to select a 21-protein multiplex panel for dementia differential diagnosis.
- Still unknown: These are observational plasma biomarker associations and retrospective diagnostic-validation results, not evidence that the proteins cause disease or improve patient outcomes. The work reports moderate rather than definitive discrimination, especially DLB versus Alzheimer dementia (validation AUC 0.78) and FTD versus Alzheimer dementia (0.77); external prospective utility remains unestablished. The later study reuses the bPRIDE cohorts and includes Alzheimer-disease analyses overlapping the group’s earlier 2025 bPRIDE plasma-proteomics paper; this entry is limited to the distinct DLB/FTD differential-marker and independent 21-plex validation findings. No individual biomarker is presented as a stand-alone clinical test.
- AI role: The analysis used 100-fold cross-validated LASSO feature selection to prioritize a limited set of disease-associated proteins and choose 21 markers for a custom multiplex assay. Pairwise logistic-regression models used selected markers to distinguish DLB and FTD from controls and Alzheimer dementia; the targeted panel was then measured in an independent multicenter validation cohort.
Evidence sources: https://www.nature.com/articles/s43587-026-01162-7
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.